Country for PR: United States
Contributor: PR Newswire New York
Thursday, August 19 2021 - 04:30
AsiaNet
MicroConstants to Join BioAgilytix Family
DURHAM, N.C., Aug. 18, 2021 /PRNewswire-AsiaNet/ --

-- Highly complementary transaction strengthens BioAgilytix's ability to 
support bioanalytical services across all major therapeutics in development; 
adds LC/MS/MS capabilities; and expands team of seasoned scientists

BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research 
laboratory focused on supporting its pharmaceutical and biotech partners in all 
stages of large molecule drug development, announced today that it signed a 
definitive agreement to acquire MicroConstants, adding it to its family of 
companies.

Logo - https://mma.prnewswire.com/media/1278852/BioAgilytix_Logo.jpg
Logo - https://mma.prnewswire.com/media/1596912/MicroConstants_Logo.jpg 

MicroConstants, to be known as BioAgilytix San Diego, provides industry-leading 
services in method development, validation, and sample analysis for small and 
large molecule therapeutics and biomarkers using LC/MS/MS, HPLC, immunoassay 
(including multiplexing and high sensitivity SIMOA) and qPCR techniques. Since 
1998, MicroConstants has supported 290+ biotechnology and pharmaceutical 
companies.

"We are excited to welcome the MicroConstants team to BioAgilytix and to work 
with them to integrate the business," said Jim Datin, President and CEO of 
BioAgilytix. "We believe that by joining forces, BioAgilytix and MicroConstants 
will not only create significant scientific and performance synergies, but also 
we are better able to serve the growing biotechnology community on the West 
Coast. Most importantly, our customers and their patients will benefit from the 
leading-edge science the combined company will bring to market."

MicroConstants, which serves clients across the pharmaceutical and biotech 
industry, has deep expertise in bioanalytical testing services with over 20+ 
years of experience performing GLP compliant bioanalytical services. The 
business will complement BioAgilytix's already impressive contract research 
services for the pharmaceutical and biotech industry. MicroConstants China 
remains a separate business entity and is not part of this transaction.

About BioAgilytix
BioAgilytix is a leading bioanalytical testing laboratory specializing in large 
molecule bioanalysis. With laboratory locations in North Carolina's Research 
Triangle area, the Cambridge area of Massachusetts, and Hamburg, Germany, 
BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay 
services supporting the development and release testing of biologics across a 
number of industries and disease states.

BioAgilytix offers assay development, validation, and sample analysis under 
non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product 
release testing, stability testing, etc.). BioAgilytix also offers diagnostic 
testing services at its CLIA-certified, CAP-accredited Boston laboratory.

BioAgilytix's team of highly experienced scientific and QA professionals 
ensures high-quality science, data integrity and regulatory compliance through 
all phases of clinical development. BioAgilytix is a trusted partner to many 
top global pharmaceutical and biotech companies. For more information, visit 
www.bioagilytix.com.

About MicroConstants, Inc.
MicroConstants Inc., is one of the largest bioanalytical LC/MS/MS service 
providers in the United States, with headquarters in San Diego, California for 
over 20 years.  MicroConstants helps its clients develop novel therapeutics by 
supporting clinical and preclinical regulated bioanalysis studies. Since 1998, 
MicroConstants has supported 290+ clients in 45 countries, completed over 8,200 
projects, and developed more than 2,400 methods. For more information on how 
MicroConstants fulfills its purpose, please visit www.microconstants.com.

Media Contact:
Pam O'Connor
BioAgilytix
+1 (919) 621-1230
pam.oconnor@bioagilytix.com

SOURCE: BioAgilytix
Translations

Japanese